BINGBING DAI to Cell Line, Tumor
This is a "connection" page, showing publications BINGBING DAI has written about Cell Line, Tumor.
Connection Strength
0.291
-
Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway. Cell Death Dis. 2021 07 10; 12(7):693.
Score: 0.065
-
Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2017 04; 16(4):662-670.
Score: 0.048
-
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy. PLoS One. 2015; 10(6):e0123967.
Score: 0.042
-
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011 May 15; 71(10):3658-68.
Score: 0.032
-
Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene. 2007 Sep 13; 26(42):6212-9.
Score: 0.024
-
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling. Cancer Med. 2019 12; 8(18):7705-7719.
Score: 0.014
-
Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Cell Death Differ. 2019 01; 26(2):382-393.
Score: 0.013
-
Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition. Oncogene. 2016 09 15; 35(37):4881-90.
Score: 0.011
-
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells. J Natl Cancer Inst. 2014 Sep; 106(9).
Score: 0.010
-
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther. 2013 Dec; 12(12):2864-73.
Score: 0.009
-
Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochem Pharmacol. 2012 May 15; 83(10):1456-64.
Score: 0.008
-
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29; 5(11):e14124.
Score: 0.008
-
Promotive effect of C/EBPepsilon overexpression on differentiation of human myelomonocytic leukemia cell line U-937. Ai Zheng. 2006 Nov; 25(11):1368-73.
Score: 0.006